Several types of drug-resistant epileptic encephalopathies of infancy have been associated with mutations in the KCNT1 gene, which encodes the sodium-activated potassium channel subunit KNa1.1. These mutations are commonly gain-of-function, increasing channel activity, therefore inhibition by drugs is proposed as a stratified approach to treat disorders. To date, quinidine therapy has been trialled with several patients, but mostly with unsuccessful outcomes, which has been linked to its low potency and lack of specificity. Here we describe the use of a cryo-electron microscopy-derived KNa1.1 structure and mutational analysis to identify the quinidine biding site and identified novel inhibitors that target this site using computational methods. We describe six compounds that inhibit KNa1.1 channels with lowand sub-micromolar potencies, likely through binding in the intracellular pore vestibule. In preliminary hERG inhibition and cytotoxicity assays, two compounds showed little effect.
Introduction
Gain-of-function mutations in the KCNT1 gene are associated with severe, drug-resistant forms of childhood epilepsy (Barcia et al., 2012; Heron et al., 2012) . Epilepsy of infancy with migrating focal seizures (EIMFS) and autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) were the first disorders found to be associated with KCNT1, with the morerecently described Ohtahara syndrome (Martin et al., 2014) , West syndrome (Ohba et al., 2015) , Lennox-Gastaut syndrome (Jia et al., 2019) , and sleep-related hypermotor epilepsy (Cataldi et al., 2019; Rubboli et al., 2019) . In addition to frequent seizures, patients may also present developmental delay, psychiatric and intellectual disabilities (Gertler et al., 1993; Lim et al., 2016) . KCNT1 encodes a sodium-activated potassium channel subunit, KNa1.1, which has previously been termed SLACK and Slo2.2 (Joiner et al., 1998; Yuan et al., 2003) .
Similar to other potassium channels, the functional proteins are formed by a tetramer of subunits, each of which possess six transmembrane alpha helices, a re-entrant pore loop between the fifth and sixth helix that forms the selectivity filter, and two intracellular regulation of conductance of potassium (RCK) domain (Hite et al., 2015) . KNa1.1-containing channels are expressed throughout the central nervous system (Bhattacharjee et al., 2002; Rizzi et al., 2016) and are believed to have a stabilising effect on the membrane potential following sodium-influx during neuronal excitation (Liu & Stan Leung, 2004; Nanou et al., 2008; Budelli et al., 2009; Hage & Salkoff, 2012; Cervantes et al., 2013) . Virtually all epilepsy-associated KCNT1 mutations increase channel activity, though why epilepsy should arise is not understood, since potassium channel opening is usually associated with a decrease in neuronal excitability. One proposed mechanism, based on studies of human stem cell-derived neurons harbouring one such mutation, is that hyperexcitability can be caused by an enhanced sodium-dependent after-hyperpolarization, facilitating an increase in the rate of action potential firing (Quraishi et al., 2019) .
Quinidine is a class I antiarrhythmic agent, which exerts its effects by non-selectively inhibiting cardiac cation channels at micromolar concentrations. Notably, quinidine also inhibits KNa1.1 channels (Yang et al., 2006) , including those harbouring epilepsy-causing mutations, at similar concentrations, leading to the hypothesis that quinidine could reverse the gain-of-function and treat KCNT1-associated epilepsy (Milligan et al., 2014; Mikati et al., 2015) . Limited improvement has been achieved in a small number of patients using quinidine therapy, but in the majority of cases it is ineffective (Mikati et al., 2015; Chong et al., 2016; Madaan et al., 2018; McTague et al., 2018; Mullen et al., 2018; Fitzgerald et al., 2019) . The lack of selectivity and low potency of quinidine in inhibiting KNa1.1 channels, with IC50 values in the order of 0.1 mM (Yang et al., 2006; Rizzo et al., 2016) , in the central nervous system without significantly affecting cardiac function is a concern and limits the dosing levels of quinidine (Mullen et al., 2018) . Moreover, there is still a paucity of information on the binding site and the mode of action of KNa1.1 inhibitors. Other reported inhibitors of KNa1.1 are bepridil (Yang et al., 2006) and clofilium (de Los Angeles Tejada et al., 2012) , both of which also have inhibitory effects on cardiac cation channels. The identification of alternative drugs that better target KNa1.1 are therefore desired (Milligan et al., 2014; Mikati et al., 2015) .
With the development of direct electron detectors, more powerful microscopes, and improved data processing software, there has been an expansion of the use of cryo-electron microscopy (cryo-EM) and single particle analysis to determine high resolution structures of membrane proteins (Rawson et al., 2016) . Bypassing the need to crystallise membrane protein samples makes this approach particularly attractive. One of the first high-resolution ion channel structures determined by cryo-EM was the chicken KNa1.1 channel, initially described at 4.5 Å resolution (Hite et al., 2015) , with the inactive and activated conformations subsequently resolved to 4.3 and 3.8 Å, respectively (Hite & MacKinnon, 2017) . The increase in resolution enables the generation of molecular models, though whether cryo-EM is presently able to deliver ion channel structural data that can be utilised in computer-aided drug discovery (CADD) or in silico drug design has not been fully explored.
In this study, we used the cryo-EM-derived structures of the KNa1.1 channel to model quinidine binding in silico. Having identified the intracellular pore vestibule as the likely site for known inhibitors to bind, we then conducted virtual high-throughput screening of a library of commercially-available compounds with the view to identify more potent and/or selective binders. We now report the identification of six diverse compounds that inhibit KNa1.1 more potently than the quinidine.
Materials & Methods

Model preparation and molecular docking
Models of the KNa1.1 pore were generated in UCSF Chimera using the atomic models of the putative closed and open tetrameric channel conformations (PDB:5U76 and 5U70, respectively (Hite & MacKinnon, 2017) , and comprised residues 244 to 340 (S 244 AMF…LWME 334 ) of each subunit. Automated docking was conducted using SwissDock (Grosdidier et al., 2011) and GLIDE (Friesner et al., 2004) in Maestro (Schrödinger). Virtual high-throughput screening was performed using GLIDE with the model of the channel in the putative open state and the Chembridge compound library consisting of 100,000 screening compounds were docked. Both protein and ligand-based docking approaches were used.
Initially the compounds were screened in HTVS mode using the inner pore vestibule as the binding site, ranked according to their predicted binding affinities and the top-scoring 10,000 compounds were taken forward and subsequently docked using the higher precision SP mode. Approximately 100 top-scoring compounds were visually inspected using PyMOL to identify the binding interactions with the protein. For the ligand-based approach, ROCs (Hawkins et al., 2007) was used to overlay the Chembridge library of compounds over the predicted bepridil binding pose. The compounds which were predicted to overlay with bepridil were subsequently docked into the inner pore vestibule to determine the predicted binding affinities and were analysed to determine whether they would form any interactions to the protein. The structures of all of the best scoring compounds from both approaches were analysed to determine the 'drug-like' properties of the molecules. Of the top-scoring compounds which fit the criteria, 17 were then ordered from Chembridge (Chembridge Corp., San Diego, CA) and were shipped as dry stocks in 1 or 5 mg quantities before being dissolved in dimethylsulphoxide to stock concentration of 10 mM.
Molecular biology and cell culture
A full-length KNa1.1 cDNA clone (IMAGE: 9054424) was obtained (Source Bioscience, Nottingham, U.K.) and the coding region subcloned into the pcDNA6-V5/His6 vector (Invitrogen). Mutations were introduced by the polymerase chain reaction using the New England BioLabs mutagenesis method and confirmed by sequencing (Genewiz, Takeley, U.K.). Due to the large size and high GC content of the insert, some mutations were generated in a plasmid containing the Bsu36I/BspEI (pore mutants) or SbfI/BsiWI (Y796H) restriction fragment and then subcloned into the corresponding sites in the pcDNA6-KNa1.1 construct. Human embryonic kidney (293) cells were cultured in Dulbecco's modified Eagle medium (DMEM with GlutaMax, Invitrogen), supplemented with 10% v/v foetal bovine serum, 50 U/ml penicillin, and 0.05 mg/ml streptomycin. Cells were co-transfected with pcDNA6-KNa1.1 and pEYFP-N1 plasmid DNA using Mirus TransIT-X2 reagent (Geneflow, Lichfield, U.K.) and were plated onto borosilicate glass cover slips for electrophysiological experiments, which were conducted 2 to 4 days later.
Electrophysiology
Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich (Gillingham, U.K.).
Patch pipettes were pulled from thin-walled borosilicate glass (Harvard Apparatus Ltd, Edenbridge, Kent, UK), polished, and gave resistances of 1.5 to 2.5 MΩ in the experimental solutions. The pipette solution contained, in mM, 100 K-Gluconate, 30 KCl, 10 Na-Gluconate, 29 Glucose, 5 EGTA and 10 HEPES, pH 7.3 with KOH and the bath solution contained, in mM, 140 NaCl, 1 CaCl2, 5 KCl, 29 Glucose, 10 HEPES and 1 MgCl2, pH 7.4 with NaOH. Currents were recorded from fluorescing cells at room temperature (20 to 22 o C) using the whole-cell patch clamp configuration using an EPC-10 amplifier (HEKA Electronics, Lambrecht, Germany), with >65 % series resistance compensation (where appropriate), 2.9 kHz low-pass filtering, and 10 kHz digitisation. For current-voltage analysis, cells were held at -80 mV and 400 ms pulses were applied to voltages between -100 and 80 mV. To evaluate inhibition by compounds, cells were held at -80 mV and 500 ms voltage ramps were applied from -100 to 40 mV at 0.2 Hz. Initially compounds, which were delivered by gravity perfusion, were applied serially at 10 µM (0.1 % final DMSO content) for 2 min, followed by at least 2 min wash with control solution before the next compound was added.
Those compounds that that exhibited at least 40% current inhibition were analysed further by concentration-inhibition analysis: G/GC = (1 + ([B]/IC50) H ) -1 + c, where G is the conductance measured as the slope of the current evoked by the voltage ramp in the presence of the inhibitor, IC is the control conductance in the absence of inhibitor, [B] is the concentration of the inhibitor, IC50 the concentration of inhibitor that yields 50% inhibition, H the slope factor, and c the residual current. For hERG currents, cells were held at -80 mV and 4 s depolarising pulses to +40 and then -50 mV were applied at 0.2 Hz. Data were analysed using Fitmaster (HEKA Electronics, Lambrecht, Germany), Microsoft Excel, and OriginPro 7.5 (OriginLab Corporation, Northampton, MA, USA). Data are presented as means ± s.e.m.
(n = number of cells). Statistical analysis was carried out using SPSS (IBM analytics, Portsmouth, UK) with p<0.05 being considered significant.
Cytotoxicity assay
Non-transfected HEK 293 cells were seeded at a density of 5x10 4 cells/ well in a 96-well plate and incubated overnight at 37°C in 5% CO2. Following exposure to three different concentrations of inhibitor for 24 hours, WST-1 reagent (Source Bioscience, Nottingham, U.K.) was added and cells were incubated for a further 2 hours. Inhibitor concentration ranges were selected to make comparison with effects on KNa1.1 currents. Cells were also treated with 10% v/v DMSO or 10 µg/ml blasticidin as positive controls. Absorbance at 450 nm (reference 650 nm) was measured using the Flexstation 3 microplate reader (Molecular Devices, Wokingham, UK). Cell viability was calculated as a percentage of the absorbance measured from untreated cells. Data were analysed using Microsoft Excel and OriginPro 7.5 (OriginLab Corporation, Northampton, MA, USA). Data are presented as mean ± s.e.m. (n = number of independent experiments). Statistical analysis was carried out using SPSS. Data were compared using an independent one-way ANOVA with Dunnett's post-hoc test; p<0.05 was considered significant.
Results
In the absence of potent and selective inhibitors of KNa1.1 potassium channels, we sought to use computational approaches to identify novel modulators. To identify a region in the KNa1.1 structure to focus in silico screening, we first sought to identify how compounds known to inhibit the channel exert their effects. Hypothesising that both quinidine and bepridil inhibit channels by occupying the inner pore vestibule we created a minimal structural model of the channel pore by removing the S1 to S4 and the cytosolic domains of the cryo-EM structures of the "closed" and "open" chicken KNa1.1 channel (Hite & MacKinnon, 2017) . Using automated procedures, both inhibitors were docked into the pore in its closed conformation at two distinct sites: in the vicinity of F346 and M354 of the S6 segment of one subunit (Fig.   1A ). In contrast, using the model of the open conformation, quinidine and bepridil could only be docked to the site involving F346 (Fig. 1A) . To validate the docking, both residues (F346 and M354) were mutated to isoleucine and serine ( Fig. 1B-C) and inhibition by quinidine and brepridil were evaluated further. Mutation of M354 had modest effects, with no significant effect on potency of quinidine, but the mutation of F346 to I346 reduced the potency approximately 10-fold (Fig. 2) . We found that mutating these pore residues, particularly F346, also increased channel activity, with respect to current amplitude and a lower degree of rectification ( Fig 1B-D) . To exclude the possibility that this was not the cause of the reduced efficacy of the inhibitors, their effects on Y796H KNa1.1, an epilepsy-causing mutation that has similar effects, were explored. This gain-of-function epilepsy mutation (Heron et al., 2012) involves a site in the intracellular RCK domains distal to the transmembrane region, and so will not directly influence the binding of compounds to the pore. In contrast to the pore mutants, quinidine inhibited this mutant channel with a 3-fold increase in potency ( Fig 2B) .
Having identified the internal vestibule, just below the selectivity filter, critical for inhibitor binding, we used this region in the minimal pore structure of the open channel conformation as the target for in silico compound screening. This approach was complemented by computational identification of compounds with structural similarity to bepridil, the most potent of the known inhibitors of KNa1.1. Both CADD techniques resulted in a list of compounds, ranked by their docking score and predicted binding affinities. A selection of 17 compounds ( Supplementary Table 1 ), based on their ranking and commercial availability were then obtained and evaluated for their ability to inhibit human KNa1.1 channels expressed in HEK cells. At 10 μM, six of the compounds inhibited KNa1.1 currents by at least 40% and were selected for further analysis (Fig. 3A) . Initially, and to validate inhibition in the inner pore vestibule, we tested the ability of these compounds to inhibit F346S KNa1.1, which had showed reduced sensitivity to both quinidine and bepridil. At 10 μM, the degree by which F346S KNa1.1 was inhibited by each compound was reduced, compared to WT KNa1.1 (Fig. 3A) . Concentration-inhibition analysis (Fig. 3B-D) yielded mean IC50 concentrations ranging 0.6 to 7.4 µM with WT KNa1.1. In comparison, quinidine and bepridil inhibited WT KNa1.1 with IC50 values in the order of 125 µM and 6.4 µM, respectively (Fig. 2 and 3D). Inspection of the location of the inhibitors docked into the KNa1.1 pore domain indicated that each bind in the inner vestibule below the selectivity filter (Fig. 4 ). Binding appears to involve both hydrophobic interaction with S6 pore-lining residues and hydrogenbonding with P-loop residues ( Fig. 4 and Supplementary Table 1 ).
The nature of the inhibition by these compounds was explored further. To be used therapeutically, KNa1.1 inhibitors would be required to inhibit channels that have epilepsycausing amino acid substitutions. We therefore explored the potency of the inhibitors with Y796H KNa1.1. Each of the six compounds inhibited mutant channels with similar potency as with WT KNa1.1, though significantly lower potency was found with BC7 and BC14 ( Fig. 3B and Supplementary Fig. 1 ). We also explored the importance of chemical groups in channel inhibition, using BC12 as an example, for which several analogues were commerciallyavailable. Each analogue failed to reduce WT KNa1.1 channel currents by more than approximately 10% at 10 μM, and were deemed inactive ( Supplementary Fig. 2) .
Finally, to anticipate toxicological effects of these novel compounds, should they or derivatives be developed further, we studied their effects on hERG potassium currents and in a cellular toxicity assay. From measurements of tail current amplitudes, 10 μM BC5, BC6, and BC7 almost completely inhibited hERG channels expressed in HEK 293 cells (>80%, Fig. 5A, B) . In contrast, BC14 had a partial effect (approx. 45%) at the same concentration, whilst BC12 and BC13 were even less effective, reducing currents by approximately 10-20%. In cytotoxicity assays, which involved exposing HEK 293 cells to compounds for 24h, only BC7 exhibited a concentration-dependent reduction in cell viability, at concentrations of 1 μM and above (Fig. 5C ). With BC5, B6, and BC14, a reduction in cell viability was found at concentrations an order of magnitude higher than the IC50, whilst BC12 and BC14 had no effect at all concentrations tested, up to and including 100 μM (Fig. 5C ). Blasticidin (10 µg/ml) and DMSO (10% v/v) reduced cell viability in the order of 45% and 90%, respectively.
Discussion
Analysis of compounds identified as potential KNa1.1 inhibitors by in silico docking yielded six previously-unknown compounds, each more potent than quinidine, which has been trialled clinically as a stratified treatment for KCNT1-associated epilepsy. The novel inhibitors described here are diverse and there is no clear pharmacophore, though BC6 and BC7 are amongst the scaffolds with structural similarity to bepridil. We propose that each of these compounds, in addition to quinidine and bepridil, inhibit the channel by blocking the pore via the intracellular vestibule. This is indicated by the reduced efficacy of each compound with the F346S pore mutation, and which is likely to be independent of the increased channel activity caused by the mutation, since with quinidine there was no similar loss of efficacy with Y796H, an epilepsy-causing mutation distal from the pore. This mode of action requires the inhibiting compound to traverse the plasma membrane and enter the pore via the cytoplasm.
It is noteworthy that each of the novel compounds tested that had a calculated logP (cLogP) value of 3.2 or less did not exhibit inhibition of KNa1.1, and this may have been as a result of poor membrane permeability. By using a model of the ion channel pore that is putatively in the open conformation, we had anticipated that the novel inhibitors would achieve similar or even higher potency with the Y796H mutant KNa1.1, but this was not always the case. It is possible that apparent increases in potency may be attributed to the high level of basal channel activity with the mutant channel and incomplete series resistance compensation, which would underestimate channel inhibition at the lower concentrations. The increase in potency of quinidine with Y796H, relative to WT KNa1.1, however, is consistent with previous studies of other gain-of-function mutations (Rizzo et al., 2016) .
Whilst the cryo-EM structures indicate that activation by sodium involves an expansion of the intracellular pore vestibule (Hite & MacKinnon, 2017) , functional experiments with this and the closely-related KNa1.2 and KCa1.1 (BKCa) channels point to the selectivity filter and proximal hydrophobic residues, rather than an S6 helix bundle, as the location of the channel gate (Garg et al., 2013; Suzuki et al., 2016; Giese et al., 2017; Jia et al., 2018) . This means that the inhibitors described here block at the channel gate and this should be a mode of inhibition that is efficacious with virtually all clinical gain-of-function mutations, independent of the mechanism by which increased open probability if achieved, rather than an inhibitor that binds to modulatory sites. An exception, however, may be the F346L mutation, which appears to have effects analogous to the F346 mutations described here, and which has already been shown to be resistant to block by 300 μM quinidine in a Xenopus oocyte expression system (McTague et al., 2018) , though the pharmacological effects of quinidine on channels containing a mixture of F346L and wild-type subunits has not been explored.
Notwithstanding our preliminary efforts to characterise the potential toxicity of these inhibitors by studying inhibition of hERG channel currents and the effects in cell viability assays, we are unable to make any statement regarding their selectivity or safety ahead of any in vitro or in vivo investigation. Since the computational approach was based on the inhibition by quinidine and bepridil, one might expect a similar range of ion channels to be inhibited by the compounds described here. However, the low level of inhibition of hERG at 10 μM by BC12 and BC13, suggests that across the compounds there may be varying levels of selectivity, which could be further improved by synthesis and analysis of derivative compounds and testing their effects on a range of different cation channels. We do note, however, the characteristics of pan-assay interference (PAINS) in compounds BC6, BC7, and BC13, due to the presence of the conjugated carbonyl group, meaning there may be non-specific effects in other functional assays. The lack of effects of the four analogues of BC12 tested demonstrate the potential for generating an inhibitor pharmacophore from this compound, thus these may provide starting points for the development of more potent inhibitors.
The generation of high-resolution structural data by cryo-electron microscopy and single particle analysis has revolutionised structural biology. Importantly, circumventing the need to crystallise samples means that membrane proteins are more amenable to analysis, and also that human proteins, rather than homologues from prokaryotes and lower eukaryotes, now feature more prominently. This means that for in silico analysis and drug discovery, target proteins very close to human, if not the human protein itself, can be utilised. The pore domain of the chicken KNa1.1 subunit, however, is virtually identical to that of the human homologue and we demonstrate its suitability for in silico docking experiments. Our study, in addition to identifying novel KNa1.1 inhibitors, provides an exemplification of the use of cryoelectron microscopy-generated membrane protein structural data in structure-based drug discovery. IC50 for WT, 124.99 ± 34.52 μM (n=5 cells); F346I, 736.08 ± 94.09 μM (n=5); F346S, 1.23 ± 0.19 mM (n=4); M354I, 99.23 ± 49.61 (n=5); M354S, 247.16 ± 19.96 μM (n=5); Y796H, 38.00 ± 12.89 μM (n=5). C Concentration-inhibition plots for wildtype and mutant KNa1.1 channels in response to 0.3μM-100μM bepridil. IC50 for WT, 6.36 ± 2.12 μM (n=5); F346I, 35.91 ± 11.01μM (n=4); F346S, 23.43 ± 5.17 μM (n=5). 
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